TM6SF2 and metabolic dysfunction-associated steatotic liver disease: Although recent GWAS studies show that the TM6SF2 gene variant is associated with a small increase in the risk of diabetes in 452,244 individuals from 54 studies (OR 1.07 [1.05−1.10], p = 4.8 × 10−12) (Mahajan et al., 2018), the TM6SF2 gene variant has a much larger effect size on NAFLD (OR 2.13 [1.36−3.30], p = 0.0009) than T2D (Pirola and Sookoian, 2015).